Shots:

• NMPA’s CDE has approved the IND application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer. The US FDA has cleared the IND of the therapy in Jun’2021
• The P-I/II study will evaluate the safety in MIBC patients- to determine RP2D and to assess efficacy as neoadjuvant therapy for MIBC
• APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic- anti-tumor activities and can also modulate tumor immune microenvironment

  | Ref: PR Newswire | Image: Asieris